ContraFect Corp (NASDAQ:CFRX) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 461,600 shares, a drop of 18.8% from the May 30th total of 568,600 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average daily trading volume, of 1,140,000 shares, the days-to-cover ratio is presently 0.4 days.
ContraFect stock remained flat at $$0.48 during midday trading on Thursday. The company’s stock had a trading volume of 84,283 shares, compared to its average volume of 1,073,397. The company has a 50-day moving average price of $0.47. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.20. ContraFect has a 52 week low of $0.35 and a 52 week high of $2.93. The firm has a market capitalization of $38.94 million, a price-to-earnings ratio of -1.30 and a beta of 0.08.
ContraFect (NASDAQ:CFRX) last released its quarterly earnings results on Friday, May 10th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.26. Equities analysts predict that ContraFect will post -0.07 EPS for the current year.
Several hedge funds have recently made changes to their positions in the company. White Pine Capital LLC raised its holdings in shares of ContraFect by 207.9% during the first quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 612,700 shares during the last quarter. Hartwell J M Limited Partnership lifted its stake in ContraFect by 150.0% in the first quarter. Hartwell J M Limited Partnership now owns 100,000 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 60,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of ContraFect by 8.3% during the 4th quarter. Geode Capital Management LLC now owns 377,908 shares of the biotechnology company’s stock worth $578,000 after buying an additional 29,009 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of ContraFect by 46.5% during the 4th quarter. Northern Trust Corp now owns 114,131 shares of the biotechnology company’s stock worth $175,000 after buying an additional 36,239 shares during the last quarter. 37.60% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have commented on CFRX shares. Maxim Group started coverage on ContraFect in a research note on Tuesday, June 11th. They issued a “buy” rating for the company. Chardan Capital reiterated a “buy” rating on shares of FORESIGHT AUTON/S in a research note on Wednesday, May 15th. Finally, ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Further Reading: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.